Management Communication – C204 Task 2 Executive Summary.docx Management Communication – C204 Nasaquil Executive Summary Nasaquil Exclusive Mel Co has been granted the exclusive contract to distribute the newest
...
Management Communication – C204 Task 2 Executive Summary.docx Management Communication – C204 Nasaquil Executive Summary Nasaquil Exclusive Mel Co has been granted the exclusive contract to distribute the newest over the counter flu treatment Nasaquil. This revolutionary new medication will change the way the influenza virus is treated for everyone. Weather a consumer is diagnosed by medical professional or just suspects that they have the flu, they can begin treatment to lessen the symptoms and shorten the duration of the illness. Target According to estimates by the CDC, October 1, 2018, thru February 16, 2019, there were approximately nineteen million flu related illnesses in the United States. Around eight to nine million of these turned into flu-related medical visits. Our target consumer is these nineteen million who had the flu and specifically the eight to nine million who went into the doctor or ER for diagnosis. Because of our companies extensive relationships in the medical community there is great anticipation for the success of this new medication. Risk and Reward There are several risks associated with this new product launch. Two specifically- one, our business partner Pruhart Tech and availability of the specialized refrigerated shipping containers required for overnight shipping of the medication. We will work with Pruhart Tech to ensure their manufacturing operation will be able to handle demand. Second, due to the limited clinical trials of a new medications efficacy in a small group of patients over a li. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .. .. . . . . . . . . . . . . . . . . . .. . . . .
[Show More]
